- -

Optimizing strategies for meningococcal C disease vaccination in Valencia (Spain)

RiuNet: Institutional repository of the Polithecnic University of Valencia

Share/Send to

Cited by

Statistics

Optimizing strategies for meningococcal C disease vaccination in Valencia (Spain)

Show full item record

Pérez Breva, L.; Villanueva Micó, RJ.; Villanueva-Oller, J.; Acedo Rodríguez, L.; Santonja, F.; Moraño Fernández, JA.; Abad, R.... (2014). Optimizing strategies for meningococcal C disease vaccination in Valencia (Spain). BMC Infectious Diseases. 14(280):1-7. doi:10.1186/1471-2334-14-280

Por favor, use este identificador para citar o enlazar este ítem: http://hdl.handle.net/10251/62462

Files in this item

Item Metadata

Title: Optimizing strategies for meningococcal C disease vaccination in Valencia (Spain)
Author: Pérez Breva, Lina Villanueva Micó, Rafael Jacinto Villanueva-Oller, Javier Acedo Rodríguez, Luis Santonja, Francisco-J. Moraño Fernández, José Antonio Abad, Raquel Vázquez, Julio A. Díez Domingo, Javier
UPV Unit: Universitat Politècnica de València. Departamento de Matemática Aplicada - Departament de Matemàtica Aplicada
Issued date:
Abstract:
Background: Meningococcal C (MenC) conjugate vaccines have controlled invasive diseases associated with this serogroup in countries where they are included in National Immunization Programs and also in an extensive catch-up ...[+]
Subjects: Meningococcal C conjugate vaccines , Seroprotection study , Agent-based modelling , Vaccination programs
Copyrigths: Reconocimiento (by)
Source:
BMC Infectious Diseases. (issn: 1471-2334 )
DOI: 10.1186/1471-2334-14-280
Publisher:
BioMed Central
Publisher version: http://dx.doi.org/10.1186/1471-2334-14-280
Description: © 2014 Pérez-Breva et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Thanks:
This paper has been supported by grant FIS PI-10/01433 from the Instituto de Salud Carlos III, and grant PAID-06-11 ref: 2087 from the Universitat Politecnica de Valencia. An agreement between CSISP-FISABIO and Baxter ...[+]
Type: Artículo

References

Trotter CL, Gay NJ, Edmunds WJ: The natural history of meningococcal carriage and disease. Epidemiol Infect. 2006, 134: 556-566. 10.1017/S0950268805005339.

Fernández S, Arreaza L, Santiago I, Malvar A, Berrón S, Vázquez JA, Hervada X, Gestal JJ: Carriage of a new epidemic strain of Neisseria meningitidis and its relationship with the incidence of meningococcal disease in Galicia, Spain. Epidemiol Infect. 1999, 123: 349-357. 10.1017/S0950268899003027.

Comité Asesor de Vacunas: Meningococo C. [ http://vacunasaep.org/profesionales/enfermedades/meningococo-c ] (accessed May 9th, 2013)., [+]
Trotter CL, Gay NJ, Edmunds WJ: The natural history of meningococcal carriage and disease. Epidemiol Infect. 2006, 134: 556-566. 10.1017/S0950268805005339.

Fernández S, Arreaza L, Santiago I, Malvar A, Berrón S, Vázquez JA, Hervada X, Gestal JJ: Carriage of a new epidemic strain of Neisseria meningitidis and its relationship with the incidence of meningococcal disease in Galicia, Spain. Epidemiol Infect. 1999, 123: 349-357. 10.1017/S0950268899003027.

Comité Asesor de Vacunas: Meningococo C. [ http://vacunasaep.org/profesionales/enfermedades/meningococo-c ] (accessed May 9th, 2013).,

Larrauri A, Cano R, Garcia M, Mateo S: Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain. Vaccine. 2005, 23: 4097-4100. 10.1016/j.vaccine.2005.03.045.

Situación actual de la enfermedad meningocócica en España: Modificación de la pauta de vacunación frente a meningococo C. Available at: [ https://www.msssi.gob.es/ciudadanos/proteccionSalud/infancia/docs/MenC_MARZO_2006.pdf ] (Accessed May 9th, 2013).,

Pérez-Breva L, Martínez-Beneito MA, Alemán-Sánchez S, Morant-Talamante N, Pérez-Vilar S, Puig-Barberà J, Díez-Domingo J: Meningococcal, C conjugate vaccine coverage in Valencia, Spain. Estimation by a multiple imputation analysis. Poster presentation at the 31st annual meeting of the European Society for Paediatric Infectious Diseases. May 28-June 1; 2013, Milan, Italy,

Pérez-Breva L, Alemán-Sánchez S, Morant-Talamante N, Abad-Torreblanca R, Sastre-Cantón M, Vázquez-Moreno J, Díez-Domingo J: Meningococcal, C seroprevalence study. Valencia. Spain. Poster presentation at the 30th annual meeting of the European Society for Paediatric Infectious Diseases. May 8-12. 2012, Thessaloniki, Greece,

Diez-Domingo J, Planelles-Cantarino MV, Baldo-Torrenti JM, Úbeda-Sansano I, Jubert-Rosich A, Puig-Barberà J, Gutiérrez-Gimeno MV: Antibody persistence 12 months after a booster dose of Meningococcal-C conjugated vaccine in the second year of life. Pediatr Infect Dis J. 2010, 29 (8): 768-770. 10.1097/INF.0b013e3181d9e653.

Revisión del programa de vacunación frente a enfermedad meningocócica por serogrupo C. Available at [ http://www.msssi.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/docs/MenC.pdf ] (Accessed, June 18, 2013).,

Maslanka SE, Gheesling LL, Libutti DE, Donaldson KE, Harakeh HS, Dykes JK, Arhin FF, Devi SJ, Frasch CE, Huang JC, Kriz-Kuzemenska P, Lemmon RD, Lorange M, Peeters CC, Quataert S, Tai JY, Carlone GM, The Multilaboratory, Study Group: Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. Clin Diagn Lab Immunol. 1997, 4 (2): 156-67.

Portero-Alonso A, Pastor-Villalba E, Marín-Ivorra R, Escuder-Alejos A, Palau-Sendra T, Chapado-Gregorio S, Lluch-Rodrigo JA, Sánchez-Latorre V, Martínez-Sorando L, Sirera-Serrano M: Sistema de información vacunal (SIV). Available at: [ http://www.sp.san.gva.es/biblioteca/publicaciones/MATERIAL/PUBLICACIONES/PROMO_SALUD/CSP/SISTEMA _ INFORMACION_VACUNAL.PDF] (Accessed, April 22, 2013),

Valentian Institute of Statistics. [ http://www.ive.es ],

Optimizing strategies for meningococcal C disease vaccination in Valencia, Spain. Data analysis at the webpage: [ http://menc.imm.upv.es ],

Poellabauer EM, Pavlova BG, Fritsch S, Singer J, Neubauer C, Doralt J, Valenta-Singer B, Ehrlich HJ: Single priming dose of meningococcal group C conjugate vaccine (NeisVac-C®;) in infants. Vaccine. 2013, [ http://dx.doi.org/10.1016/j.vaccine.2013.04.070 ],

Cano R, Larrauri A, Mateo S, Alcalá B, Salcedo C, Vázquez JA: Impact of the meningococcal C conjugate vaccine in Spain: an epidemiological and microbiological decision. Euro Surveill. 2004, 9: 5-6.

Balmer P, Borrow R, Miller E: Impact of meningococcal C conjugate vaccine in the UK. Med Microbiol. 2002, 51: 717-722.

Fitzgerald M, O‘Donnell J, O‘Flanagan D, Cafferkey M, Murphy K: Meningococcal disease in Ireland since the introduction of meningococcal serogroup C conjugate vaccination. Euro Surveill. 2004, 8 (5): 2376-

De Greef S, Ruijs H, Timen A, van Deuren M, de Vries M, de Melker H, Spanjaard L, Dankert J: First effects of meningococcal C vaccination campaign in Netherlands. Euro Surveill Weekly. 2003, 7 (30): 2264-

Trotter CL, Gay NJ, Edmunds WJ: Dynamic models of meningococcal carriage, disease, and the impact of serogroup C conjugate vaccination. Am J Epidem. 2005, 162: 89-100. 10.1093/aje/kwi160.

[-]

This item appears in the following Collection(s)

Show full item record